Findings from the ReNeu trial showed treatment with mirdametinib resulted in statistically significant objective response rates. The Food and Drug Administration (FDA) has accepted for Priority Review ...
Neurofibromatosis type 1 (NF1) is a rare genetic disorder that affects the nervous system, causing tumors to form on nerves throughout the body. It is also known as Von Recklinghausen disease, named ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback